Doctor Arzu Kalayci Karabay
Harvard Medical School, Boston (United States of America)
Member of:
/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
/f/125658/3386x1417/951de003e4/hfa-acronym-name-rgb.png)
Betrixaban versus enoxaparin for venous thromboembolism prophylaxis in critically ill patients: findings from the APEX trial
Event: ESC Congress 2018
Topic: Venous Thromboembolism
Session: Progress in anticoagulation for venous thromboembolism
Asymptomatic deep vein thrombosis in acutely ill medical patients: insights from the APEX trial
Event: ESC Congress 2018
Topic: Venous Disease
Session: Venous thrombosis and anticoagulation
ESC 365 is supported by
